Baudax Bio (BXRX) Stock

As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dramatic winner. Earlier Thursday morning, management disclosed that the U.S. Food and Drug Administration (FDA) granted its lead clinical candidate orphan drug designation.

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug status by the United States Food and Drug Administration (FDA). Its lead candidate TI-168 is a FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases.

Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight, skyrocketing into triple-digit percentage gains. The pharmaceutical company — which focuses on innovative products for acute care — announced the acquisition of Teralmmune, a privately held biotechnology firm focused on autoimmune disease therapies.

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune diseases. TeraImmune has a cell therapy candidate to eliminate certain clotting factor inhibitors in patients with hemophilia A, a rare genetic bleeding disorder, Baudax said in a release.

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.